Special Issue "From the Bench to the Clinic: Lessons in the Use of Neurotoxins as Research and Therapeutic Tools"

A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".

Deadline for manuscript submissions: 31 May 2022.

Special Issue Editors

Dr. Célia Duarte Cruz
E-Mail Website
Guest Editor
Department of Biomedicine – Experimental Biology Unit, Faculty of Medicine/i3S -i3S - Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal
Dr. Karen McCloskey
E-Mail
Co-Guest Editor
Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK

Special Issue Information

Dear Colleagues,

What is a neurotoxin? Produced by plants, animals, and single-cell organisms, neurotoxins are chemicals that target nervous tissue. Many are deleterious and dangerously interfere with normal physiology in adults and impair neurodevelopment. Yet, some neurotoxins have found their way into laboratories as useful tool compounds and are widely used to answer fundamental questions about physiology at the cellular, tissue, organ, and systems level. After years of research and refinement, some are now used as therapeutic tools to treat pathologies from movement disorders to urinary dysfunction. Despite these advances, much is still to be discovered in the field of neurotoxins, whether by characterizing newly identified molecules or elucidating the molecular mechanisms of action of specific neurotoxins. Therefore, for this Special Issue, we invite authors to present their work addressing these exciting topics.

Dr. Célia Duarte Cruz
Dr. Karen McCloskey
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Tetrodotoxin
  • botulinum toxin
  • tetanus toxin
  • resiniferatoxin
  • capsaicin
  • bungarotoxin
  • clinical translation
  • translational research

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Botulinum Toxin Type A for Glabellar Frown Lines: What Impact of Higher Doses on Outcomes?
Toxins 2021, 13(7), 494; https://0-doi-org.brum.beds.ac.uk/10.3390/toxins13070494 - 16 Jul 2021
Viewed by 824
Abstract
Botulinum toxin serotype-A (BoNT-A) preparations are widely used to improve the appearance of wrinkles. While effective and well tolerated, patients require retreatment over time to re-establish the effects. There is growing interest from patients as to whether higher doses can prolong response without [...] Read more.
Botulinum toxin serotype-A (BoNT-A) preparations are widely used to improve the appearance of wrinkles. While effective and well tolerated, patients require retreatment over time to re-establish the effects. There is growing interest from patients as to whether higher doses can prolong response without significantly increasing side effects. We reviewed the efficacy and safety evidence for high-dose BoNT-A treatment of glabellar lines, by evaluating high-dose studies published since 2015. Toxins approved for glabellar line treatment in the US or Europe were considered. “High-dose” indicated doses above the licensed dose for each BoNT-A preparation. Five studies met the inclusion criteria and most were randomized, double-blind trials; designs and population sizes varied. Findings suggested that higher-dose BoNT-A treatment is feasible and may improve response duration without increased safety issues. Around 9 months’ median duration was achieved with a 2–2.5-fold increase of the abobotulinumtoxinA on-label dose, or with a 5-fold increase in incobotulinumtoxinA dose. A 2–4-fold increase of the onabotulinumtoxinA on-label dose yielded a median duration of around 6 months. Importantly, patient satisfaction and natural look remained with increasing abobotulinumtoxinA doses. While more data are needed, these findings may lead to more effective, individually tailored treatment plans to meet patient expectations. Full article
Back to TopTop